Indonesia Secures Drug Supply with Remdesivir, Favipiravir Patents
Indonesia President Joko "Jokowi" Widodo issued regulations to fulfill the availability of COVID-19 drugs, Remdesivir and Favipiravir, as stipulated in the Presidential Regulation (Perpres) No. 100/2021 and 101/2021 on patents for Remdesivir and Favipirapir. "The government needs to establish a policy on access to drugs that are currently still protected by patents," reads the second consideration of the regulation, released on November 10.
The regulation stipulates that the government patents on Remdesivir and Favipiravir will run for three years with possible extension if the COVID-19 pandemic has not ended. The Health Minister will appoint the pharmaceutical industry as the patents executor. The appointed pharmaceutical manufacturer will carry out the duties of implementing the Favirapir and Remdesivir patents on a limited basis.